A needle-free patch form of BPC-157 (a peptide used to treat injuries) is moving closer to becoming available to the general public. The patch lets people use the drug without injections.

• •A needle-free patch version of BPC-157 is moving toward a mainstream launch
• •The patch would let users take BPC-157 without injections

The Precision Peptide Company is moving toward selling a patch version of BPC-157 (a peptide used to help with healing) that doesn't need a needle. The company is finishing final tests before launching the product commercially.

• •The Precision Peptide Company is developing a needle-free BPC-157 patch
• •Product is in final testing before a planned commercial launch

HYTN Innovations plans to split off its BPC-157 peptide drug business into a separate company. BPC-157 is a peptide being developed as a potential treatment for various conditions.

• •HYTN Innovations plans to spin out its BPC-157 peptide drug business
• •The spin-out would create a separate company focused on BPC-157
• •BPC-157 is being developed as a potential treatment

• •Article covers BPC-157, an experimental peptide with no approved drug status

HYTN is starting a new company focused on BPC-157, a peptide drug candidate, and plans to raise $1 million to fund it. The move splits BPC-157 development into its own separate business unit.

• •HYTN plans to spin out BPC-157 into a separate drug company
• •The new entity is targeting a $1 million raise